The PFKFB3 (6-phosphofructo-2-kinase/fructose-2.6-biphosphatase 3) antibody is a critical tool for studying the role of PFKFB3. a bifunctional enzyme central to regulating glycolytic flux. PFKFB3 catalyzes the synthesis and degradation of fructose-2.6-bisphosphate (F2.6-BP), a potent allosteric activator of phosphofructokinase-1 (PFK-1), a rate-limiting enzyme in glycolysis. By modulating F2.6-BP levels, PFKFB3 enhances glycolytic activity, enabling cells—particularly cancer cells—to meet their high energy and biosynthetic demands. This enzyme is often overexpressed in tumors, where it supports the Warburg effect (aerobic glycolysis), angiogenesis, and cell proliferation, making it a target for cancer therapeutics.
PFKFB3 antibodies are widely used in research to detect protein expression, localization, and dynamics in tissues or cell lines under various conditions, such as hypoxia or metabolic stress. They facilitate techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Studies also employ these antibodies to explore PFKFB3's interplay with signaling pathways (e.g., HIF-1. AMPK) and its role in diseases beyond cancer, including diabetes, ischemia-reperfusion injury, and inflammatory disorders. Inhibitors targeting PFKFB3 are under investigation, and corresponding antibodies help validate target engagement or monitor downstream effects in preclinical models. Overall, PFKFB3 antibodies are vital for unraveling metabolic adaptations in health and disease.
(Word count: 200)